Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

N/AEnrolling By InvitationNCT06624189

NYU Langone Health600 enrolled

Overview

The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Hepatocellular Carcinoma Cirrhosis

Interventions

Auto-pended bot liver ultrasound orderOTHER

This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * cirrhosis diagnosis, * 6 months or more after since most recent imaging. Exclusion Criteria: * previous liver transplant, * HCC diagnosis, * receiving hospice care, * completed external imaging in the past 6 months.

Locations (1)

NYU Langone Health

New York, New York, United States

Outcomes

Primary Outcomes

Percentage of Participants for whom the Physician Completed Ordering of the Pending Liver Ultrasound

Time frame: Day 1

Secondary Outcomes

Percentage of Participants with Completed Liver Ultrasound Imaging

Time frame: Day 1

HCC Diagnosis Rate from Completed Liver Ultrasound Imaging

Time frame: Day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.